Omeros Co. (NASDAQ:OMER) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Omeros Co. (NASDAQ:OMER) have earned an average recommendation of “Moderate Buy” from the five research firms that are presently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $22.50.

A number of research firms recently weighed in on OMER. RODMAN&RENSHAW raised shares of Omeros to a “strong-buy” rating in a research report on Thursday, November 14th. StockNews.com raised Omeros from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Cantor Fitzgerald reissued a “neutral” rating on shares of Omeros in a report on Thursday, November 14th. D. Boral Capital reissued a “buy” rating and set a $36.00 target price on shares of Omeros in a report on Thursday. Finally, Rodman & Renshaw started coverage on shares of Omeros in a research report on Thursday, November 14th. They issued a “buy” rating and a $9.00 price target for the company.

Hedge Funds Weigh In On Omeros

Institutional investors have recently modified their holdings of the business. BNP Paribas Financial Markets lifted its stake in Omeros by 130.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 7,016 shares during the last quarter. MML Investors Services LLC lifted its holdings in Omeros by 19.2% during the 3rd quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock worth $74,000 after buying an additional 3,000 shares during the period. SPC Financial Inc. acquired a new position in shares of Omeros in the third quarter worth approximately $77,000. SG Americas Securities LLC acquired a new position in shares of Omeros in the 3rd quarter worth approximately $80,000. Finally, AQR Capital Management LLC acquired a new position in Omeros in the second quarter valued at $105,000. Institutional investors and hedge funds own 48.79% of the company’s stock.

Omeros Stock Performance

NASDAQ:OMER opened at $9.18 on Friday. Omeros has a 52-week low of $2.61 and a 52-week high of $13.60. The company has a market cap of $531.98 million, a PE ratio of -3.97 and a beta of 2.01. The stock has a 50-day simple moving average of $9.25 and a 200 day simple moving average of $5.96.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.